Injury Indicators Sample Clauses

Injury Indicators. All Injuries 9 Unintentional Falls 11 Unintentional Fire-Related Injuries 13 Firearm-Related Injuries 15 Homicide and Assault 17 Unintentional Motor Vehicle Traffic Crashes 19 Non-Drug Poisoning 21 Drug Poisoning 23 Suicide and Self-Injury 25 Traumatic Brain Injury 27 Abbreviations CDC Centers for Disease Control and Prevention CSTE Council of State and Territorial Epidemiologists ED emergency department ICD International Classification of Diseases ICD-CM International Classification of Diseases, Clinical Modifications KIPRC Kentucky Injury Prevention and Research Center MV motor vehicle ATV all-terrain vehicle PCR police collision report TBI traumatic brain injury Executive Summary Kentucky’s overall age-adjusted injury mortality rate was 84.4 per 100,000 Kentucky resident population in 2018. The male and female age-adjusted rates were 118.9 and 51.5, respective- ly. The age-adjusted rate for injury-related inpatient hospitalizations per 100,000 population was 475.5 per 100,000 Kentucky resident population in 2018. The male and female age-adjusted rates were 466.6 and 469.0, respectively. The age-adjusted rate for injury-related emergency department visit discharges per 100,000 Kentucky resident population was 10,850 in 2018. The male and female age-adjusted rates were 11,028.4 and 10,614.1, respectively. Mortalities There were 3,841 injury mortalities among Kentucky residents in 2018. The leading mecha- nisms of injury mortality for Kentucky residents in 2018 were poisonings (1,319), firearms (719), and motor vehicle traffic crashes (626). Ninety five percent of the poisonings were drug poisonings. Among the drug poisonings (1,250), 95% were unintentional drug overdoses in- volving prescription medications and/or illicit drugs. The leading injury mechanisms among in- tentional deaths (suicides and homicides) were firearms (68%) and suffocation/hanging (19%). There were 962 mortalities from traumatic brain injuries (TBI), where TBI was reported as a cause of death on the death certificate alone or in combination with other injuries or conditions. TBI-related mortalities were either intentional (50%) or unintentional (50%). Inpatient Hospitalizations There were 23,379 injury-related inpatient hospitalization encounters among Kentucky resi- dents in 2018. The leading mechanisms of injury-related inpatient hospitalizations were falls (11,991), drug poisonings (3,609), and motor vehicle traffic crashes (2,474). The majority of unintentional fall-related hospi...
Sample 1
AutoNDA by SimpleDocs
Injury Indicators. All Causes of Injury 4 Unintentional Falls 6 Unintentional Fire-related Injuries 8 Firearm-Related Injuries 10 Homicide and Assault 12 Motor Vehicle Traffic Crashes 14 Poisoning 16 Suicide and Self-Injury 18 Executive Summary* Kentucky’s overall age-adjusted injury mortality rate increased by over 8% in year 2015 compared to year 2014 (from 79.9 per 100,000 population to 88.7/100,000). The three leading causes of injury mortality in Kentucky — poisonings (33%), suicides (19%), motor vehicle traffic crashes (19%) — all increased over year 2014 levels. The injury morbidity rate in Kentucky, as measured by hospitalization discharges, has steadily declined in recent years. In year 2015 this decline continued, with the age-adjusted rate of all cause injury-related hos- pitalizations per 100,000 population decreasing by 7.6% from 500.0 in 2014 to 492.4 in 2015. The motor vehicle traffic-related injury hospitalization discharge rate decreased, whereas, the rates for self-injuries (from 43.4 to 44.9 per 100,000 population) and poisonings (from 93.6 to 98.3 per 100,000 population), that include drug overdoses, increased. Fatalities* The leading causes of injury mortality in Kentucky residents in year 2015 were poisonings (1,316), suicides (761), and motor vehicle traffic crashes (757). Of the 1,316 poisonings, 1,238 (94%) were drug overdoses involving prescription medications and/or illicit drugs. The leading causes of violent deaths were suicide by firearm (494), suicide by suffocation/hanging (176), and homicide by firearm (173). Traumatic brain injury** (TBI) accounted for 989 fatalities. Hospitalizations* The leading causes of injury-related hospitalizations in Kentucky were unintentional falls (11,582), poison- ings (4,352), and motor vehicle traffic crashes (2,478). The leading cause of unintentional fall-related hospi- talizations was due to falls occurring on the same level (3,841). Of the 4,352 poisonings, 1,770 (41%) were suicidal, 1,587 (36%) unintentional, and 991 (23%) undetermined intents. TBI** accounted for 2,952 hospi- talizations.
Sample 1
Injury Indicators. All Injuries 9 Unintentional Falls 11 Unintentional Fire-Related Injuries 13 Firearm-Related Injuries 15 Homicide and Assault 17 Unintentional Motor Vehicle Traffic Crashes 19 Non-Drug Poisoning 21 Drug Poisoning 23 Suicide and Self-Injury 25 Traumatic Brain Injury 27 Abbreviations CDC Centers for Disease Control and Prevention CSTE Council of State and Territorial Epidemiologists ED emergency department ICD International Classification of Diseases ICD-CM International Classification of Diseases, Clinical Modifications KIPRC Kentucky Injury Prevention and Research Center MV motor vehicle ATV all-terrain vehicle PCR police collision report TBI traumatic brain injury Executive Summary Kentucky’s overall age-adjusted injury mortality rate was 84.4 per 100,000 Kentucky resident population in 2018. The male and female age-adjusted rates were 118.9 and 51.5, respective- ly. The age-adjusted rate for injury-related inpatient hospitalizations per 100,000 population was 475.5 per 100,000 Kentucky resident population in 2018. The male and female age-adjusted rates were 466.6 and 469.0, respectively. The age-adjusted rate for injury-related emergency department visit discharges per 100,000 Kentucky resident population was 10,850 in 2018. The male and female age-adjusted rates were 11,028.4 and 10,614.1, respectively.
Sample 1
Injury Indicators. All causes of injury 5 Unintentional Falls 7 Unintentional Fire-related Injuries 9 Firearm-Related Injuries 11 Homicide and Assault 13 Motor Vehicle Traffic Crashes 15 Poisoning 17 Suicide and Self-Injury 19
Sample 1

Related to Injury Indicators

  • Performance indicators and targets The purpose of the innovation performance indicators and targets is to assist the University and the Commonwealth in monitoring the University's progress against the Commonwealth's objectives and the University's strategies for innovation. The University will report principal performance information and aim to meet the innovation performance indicators and targets set out in the following tables.

  • Performance Indicators The HSP’s delivery of the Services will be measured by the following Indicators, Targets and where applicable Performance Standards. In the following table: n/a meanç ‘not-appIicabIe’, that there iç no defined Performance Standard for the indicator for the applicable year. tbd means a Target, and a Performance Standard, if applicable, will be determined during the applicable year. INDICATOR CATEGORY INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator 2019/20 PERFORMANCE TARGET STANDARD Organizational Health and Financial Indicators Debt Service Coverage Ratio (P) 1 c1 Total Margin (P) 0 cO Coordination and Access Indicators Percent Resident Days – Long Stay (E) n/a n/a Wait Time from LHIN Determination of Eligibility to LTC Home Response (M) n/a n/a Long-Term Care Home Refusal Rate (E) n/a n/a SCHEDULE D — PERFORMANCE 2/3 INDICATOR CATEGORY Quality and Resident Safety Indicators INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator Percentage of Residents Who Fell in the Last 30 days (M) 2019/20 PERFORMANCE TARGET STANDARD n/a n/a Percentage of Residents Whose Pressure Ulcer Worsened (M) n/a n/a Percentage of Residents on Antipsychotics Without a Diagnosis of Psychosis (M) n/a n/a Percentage of Residents in Daily Physical Restraints (M) n/a n/a SCHEDULE D — PERFORMANCE 2.0 LHIN-Specific Performance Obligations 3/3

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • SHOP DRAWINGS, PRODUCT DATA AND SAMPLES 4.12.1 Shop Drawings are drawings, diagrams, schedules and other, data specially prepared for the Work by the Contractor or any Subcontractor, manufacturer, supplier or distributor to illustrate some portion of the Work.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Indicators Debt to Asset Ratio (10%) •Cash Flow (10%) •Total Margin (25%) Risk Assessment Results

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Attainment on Performance Indicators The District will be responsible for overseeing the academic programs offered in its schools and ensuring that those programs meet or exceed state and local expectations for levels of attainment on the statewide performance indicators, as specified in 1 CCR 301-1.

  • Product Coverage This Agreement shall apply to all manufactured products, - including capital goods, processed agricultural products, and those products failing outside the definition of agricultural products as set out in this Agreement. Agricultural products shall be excluded from the CEPT Scheme.

Time is Money Join Law Insider Premium to draft better contracts faster.